Exonics Therapeutics scores $5 mln seed
Boston-based Exonics Therapeutics Inc, a newly formed biotech company focused on developing gene editing technologies to Duchenne muscular dystrophy and other neuromuscular diseases, has secured $5 million in seed financing. The investor was CureDuchenne Ventures LLC.
28 February 2017•1 min read
